Gottlieb's Greatest Strength As US FDA Commissioner? Stability
Executive Summary
Amid all the praise for his raising of FDA's profile and aggressive policy stances, Scott Gottlieb's most valuable contribution while in office may have been leaving the agency fundamentally unchanged, an important lesson for incoming Acting Commissioner Norman Sharpless.
You may also be interested in...
Gottlieb: FDA Would Be Subject To More White House Control Under A Second Trump Term
The former commissioner warned that the FDA likely would get very different treatment under a second Trump term than it got under a first. Gottlieb also discussed the need for legislation to help advance ‘n of 1’ drug regulation and how to communicate uncertainty in a wide-ranging interview.
Stephen Hahn For US FDA Commissioner: Will Academic Experience Suffice For Confirmation?
The MD Anderson Cancer Center administrator's lack of significant government administration experience may inspire questions during the confirmation process.
Former FDA Commissioners Push For Sharpless Nomination, Confirmation
Five former US FDA leaders and many stakeholder groups say Acting Commissioner Norman Sharpless should be the next permanent commissioner.